Table IV.
Group | Saline (n) | NMDA receptor antagonist (n) | 2,6-diisopropylphenol (n) | Total (n) | F-statistic | P-value |
---|---|---|---|---|---|---|
Control | 39.13±6.94 | 21.50±3.59 | 20.25±2.76 | 26.96±9.92 | 38.964 | 0.000 |
ECT | 80.13±11.63 | 48.88±6.77 | 53.13±8.48 | 60.71±16.64 | 27.257 | 0.000 |
Total | 59.63±23.11 | 35.19±15.07 | 36.69±18.04 | 43.83±21.78 | 56.003a | 0.000a |
F-statistic | 73.329 | 102.138 | 108.781 | 255.037a | – | – |
P-value | 0.000 | 0.000 | 0.000 | 0.000a | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=3.507 and P=0.039;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.